SLC5A2 and type 2 diabetes mellitus: Of interest, SGLT2 inhibitors also lower serum uric acid, which may in part explain the finding that this class of drugs is also associated with improved cardiorenal risk, i.e., reduces the risk of cardiovascular events and slows progression of CKD in patients with T2D [30].